AorTech International announces John McKenna to its Board as upcoming Non-Executive Director

– UK, Weybridge – AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, announces that Eddie McDaid has informed the Board of his intention to resign, as Chief Executive Officer of the Company with effect from the 31st October 2016. Mr McDaid has served as CEO since December 2013 and having resolved a number of issues now feels it is time to retire from the Board. Bill Brown will assume CEO responsibilities.

The Directors would like to thank Mr McDaid for his contribution to and leadership of the Company whilst he served as CEO in what was a very difficult time and his substantial efforts and commitment in stabilising the business and wish him well in retirement.

The Board is pleased to announce the appointment of Mr. John McKenna, aged 63, to the Board as Non-executive Director with effect from 31st October 2016. Mr McKenna has a long and successful career in sales and marketing of medical devices, particularly in the cardio vascular sector. Mr McKenna will serve as a Non-executive Director but his focus will be on business development and exploring opportunities for AorTech to further exploit its portfolio of Intellectual Property assets.

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon and ECSil the world’s leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k’s, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon and ECSil’s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>